Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

NCT04795869 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study inactivated due to zero accruals

Conditions

Recurrent Angioimmunoblastic T-Cell Lymphoma
Recurrent Enteropathy-Associated T-Cell Lymphoma
Recurrent Follicular T-Cell Lymphoma
Recurrent Hepatosplenic T-Cell Lymphoma
Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma
Refractory Angioimmunoblastic T-Cell Lymphoma
Refractory Enteropathy-Associated T-Cell Lymphoma
Refractory Follicular T-Cell Lymphoma
Refractory Hepatosplenic T-Cell Lymphoma
Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma

Interventions

DRUG: Brentuximab Vedotin
BIOLOGICAL: Pembrolizumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]